Pompe Pregnancy Sub-Registry
Observational Study on Pregnancy Outcomes in Women with Pompe Disease
Study Overview
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Pompe disease during pregnancy, regardless of whether they receive disease-specific therapy, such as ERT with alglucosidase alfa or avalglucosidase alfa.
Study Details
Study Design Time Perspective: Retrospective and Prospective
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
-
Gender: Female
Inclusion Criteria:
Eligible women must:
- be enrolled in the Pompe registry (NCT00231400)
- be pregnant, or have been pregnant with appropriate medical documentation available.
- provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.
Note: It is recommended that pregnancy data be collected on eligible women regardless of infant enrollment. In the event of patients having multiple pregnancies, participation in this Sub-Registry is encouraged for each individual pregnancy.
Exclusion Criteria:
There are no exclusion criteria for this Sub-Registry
This study investigates pregnancy outcomes in women with Pompe disease. The study is observational, meaning it involves monitoring and collecting data on pregnant women with Pompe disease, whether or not they are receiving enzyme replacement therapy (ERT) or other treatments. The aim is to gather information on pregnancy complications and infant growth.
Participants in the study will undergo clinical assessments and receive standard care as determined by their healthcare providers. The study does not involve any experimental treatments, focusing instead on collecting data through routine care practices. An observational study is a type of research study where data is collected by observing participants receiving routine care, without changing their treatment, which may focus on people using specific medications or having certain conditions to better understand how treatments work.
- Who can participate: Women who are pregnant or have been pregnant and are enrolled in the Pompe registry are eligible to participate. They must provide informed consent and have appropriate medical documentation.
- Study details: Participants will provide data on their pregnancy outcomes, which will be collected alongside standard care by their healthcare providers. No investigational treatments are involved in this study.